Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


MERIDIAN BIOSCI   FYE=9 (September)

Annual - Income Statement - Company Specific

Fiscal period2019201820172016201520142013201220112010
Period End Date9/30/20199/30/20189/30/20179/30/20169/30/20159/30/20149/30/20139/30/20129/30/20119/30/2010
Sales201.01213.57200.77196.08194.83188.83188.69172.71158.84143.00
Total Revenues201.01213.57200.77196.08194.83188.83188.69172.71158.84143.00
Cost of sales82.6983.1176.4868.8772.9571.5967.6463.6659.9254.30
Cost of sales: Sale of product--------------------
Cost of sales: Inventory impairment--------------------
Cost of sales - Plant Consolidation----------------0.510.00
Gross Profit118.33130.46124.29127.21121.88117.24121.04109.0598.4188.70
Goodwill impairment charge----6.63--------------
Research and development17.9516.8716.0414.1912.6112.5510.7910.289.828.40
Acquired in-process research and development--------------------
Sales and marketing28.4534.4732.3930.0625.6024.9122.4222.0921.8918.25
General and Administrative33.0034.4931.1029.4327.6227.3930.5226.3724.8819.67
Sales and marketing leadership reorganization----------------1.24--
Merger integration costs----------------0.550.00
European restructuring costs--8.710.130.68------------
Costs of abandoned acquisition--------------------
Restructuring Costs2.84------------------
Bioline Group transaction costs------------------1.24
Costs and asset impairment charges related to FDA matters--------------------
Litigation costs(1.58)(4.35)(0.63)--------------
Acquisition-related costs(1.81)----(1.48)------------
Plant consolidation costs--------------(1.01)----
Total Operating Expenses85.6398.8886.9175.8365.8264.8563.7359.7558.3847.56
Operating Income (loss)32.7031.5837.3851.3856.0652.3957.3149.3040.0341.14
Interest expense--1.521.640.90------------
Interest income--0.420.170.070.020.030.040.040.120.12
Other(1.14)(0.10)0.520.10(1.02)(0.31)0.000.380.350.14
Earnings before income taxes31.5630.3836.4350.6455.0652.1157.3649.7240.5041.40
Current : State and local--1.071.902.422.241.762.011.521.21--
Income tax (benefit) provision7.186.5314.8718.4219.5217.3719.3316.3513.6714.75
Foreign--0.400.800.950.890.280.611.020.89--
Federal: Current provision--------16.1515.02--------
Federal: Fixed asset basis differences and depreciation--0.41(0.18)(0.05)0.050.110.120.00(0.16)--
Federal: Intangible asset basis differences and amortization--(4.05)(1.16)(0.74)(0.42)(0.21)(0.34)(0.35)(0.31)--
Federal: Currently non-deductible expenses and reserves--1.210.88(0.69)0.220.05(0.43)(0.40)(0.63)--
Federal: Stock based compensation--1.38(0.64)0.130.130.06(0.28)(0.60)(0.71)--
Federal: Other, net--(0.15)0.100.180.020.070.040.070.04--
Federal: Currency translation--------------------
Federal: Net operating loss carryforwards--0.061.83--------------
Federal: Abandoned acquisition costs--------------------
Federal: Tax contingency reserve adjustment--------------------
Federal: Tax credit carryforwards--0.180.070.040.250.23(0.72)------
Net Income (loss) Available to Common Shareholders24.3823.8521.5632.2335.5434.7438.0333.3726.8326.65
Net Earnings Per Share (Basic)0.570.560.510.770.850.840.920.810.660.66
Net Earnings Per Share (Diluted)0.570.560.510.760.850.830.910.800.650.65
Weighted Average Shares Outstanding (Basic)42.5742.3342.1942.0141.6641.4641.2341.0840.7240.52
Weighted Average Shares Outstanding (Diluted)42.9042.7542.5742.3942.0141.9141.9041.6141.3641.15